Rituximab Plus CHOP Compared With CHOP Alone In Patient With Initial Treatment Diffuse Large B Cell Lymphoma

Objective:To analyse the therapeutic efficacy,survival and side effects between different chemotherapy Regimes for the treatment of newly diagnosed patients、with DLBCL by retrosp-ective studies.Materials and methods:A total of 113 newly diagnosed cases with DLBCL which were diagnosed from January 2003 to December 2009 were enrollted from our hospital.The patients were divided into two groups : 47 received Rituximab plusCHOP(Cyclophosphamide,epirubicin,vincristine,prednisone)and 66 received CHOP alone.The cycle was repeated every 3weeks.The therapeutic efficacy and side effects of RCHOP and CHOP regimens were evaluated according to the revised response criteria for lymphoma after 6chemotherapy cycles.All patients were followed up for 2 years,Event free survival(EFS)and overall survival(OS)were observed.We did the statistics analysis by SPSS 19.0 sofeware.P<0.05 has statistic significance.Results:1.Effects : After 6 course of treatment,R-CHOP group of 47 cases,CR36 example,CR rate of 76.6%,PR9 example,PR rate is 19.1%,SD1 example,SD rate 2.1%,PD1 example,PD rate is 2.1%,the total effective rate was 95.7%(45/47).CHOP group,66 cases of patients,CR34 example,CR rate of 51.5%,PR10 example,PR rate was 15.2%.SD6 example,SD rate was 9.1%.New parallels,the PD rate 10.6%.5 cases of recurrence,4 cases of death,the total effective rate was 66.7%(44/66).CHOP treatment with R-CHOP on the clinical efficacy of treatment differences statistically significant(P < 0.05).2.Side effects:The major adverse reaction in R-CHOP group is infusion reaction of the first time after infusion rituxan,presented with fever,chills,and blood pressure to drop,allergy symptoms.There was no statistically significant difference in hematological adverse reactions and ther non-hematologic adverse reactions between two groups.3.After 2 years of follow-up,data analysis,27 patients R-CHOP group were no event survival(EFS was 57.4%),26 patients of CHOP group without incident,(EFS was 39.4%).Two groups compared to P < 0.05.In R-CHOP group the total survival number is 36(OS 76.6%);CHOP group total survival number is 37(OS 56.1%),P < 0.05 between the two groups.R-CHOP scheme is better than CHOP scheme in continuous complete remission.Conclusion:1.R-CHOP Was significantly associated with a better short-term efficacy and long-term efficacy than CHOP.R-CHOP can be recommended as the first。Choice regimen for the treatment of Newly Diagnosed patients with DLBCL.2.The major adverse reaction in R-CHOP group is infusion reaction of the first time after infusion rituxan,presented with fever,chills,and blood pressure to drop,allergy symptoms.There was no statistically significant difference in hematological adverse reactions and ther non-hematologic adverse reactions between two groups.3.CHOP with rituxan therapy in patients with diffuse large B cell lymphoma extended event survival rate and overall survival rate and no significant increase in the clinical toxicity.4.The appropriate reduction in the drug dose of CHOP may not affect the outcome and prognosis.